Cost-effectiveness Analysis of Carelizumab plus Paclitaxel and Carboplatin versus Sintilimab plus Gemcitabine and Cisplatin or Carboplatin for the First-line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland User montaukwhaler, in the non small cell lung cancer subreddit, 04 Jul 2024